Testosterone breakthrough and outcomes during intensified therapy in metastatic hormone-sensitive prostate cancer: the ARASENS and LATITUDE trials.
OBJECTIVES To assess whether treatment-period serum testosterone breakthrough >35 ng/dL is associated with clinical outcomes during intensified therapy for metastatic hormone-sensitive prostate cancer. PATIENTS AND METHODS We performed post hoc analyses of the experimental arms of the ARASENS (darolutamide plus andro...